Who is sponsoring NCT03562741?

NCT03562741 is sponsored by Krunal Patel.

What drugs are being tested in NCT03562741?

Interventions in NCT03562741: Fecal Microbiota Transplantation.

What condition does NCT03562741 study?

NCT03562741 studies Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection.

Is NCT03562741 still recruiting?

NCT03562741 is currently recruiting now. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT03562741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile

Recruiting now NA Last updated 20 February 2026

What this trial tests

NA trial testing Fecal Microbiota Transplantation in Clostridium Difficile Infection Recurrence in 500 participants. Currently enrolling.

Timeline

16 January 2014

Primary endpoint
16 January 2028

16 January 2029

Quick facts

Lead sponsor	Krunal Patel
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	16 January 2014
Primary completion	16 January 2028
Estimated completion	16 January 2029
Sites	1 location across United States

Drugs / interventions tested

Fecal Microbiota Transplantation — full drug profile →

Conditions studied

Clostridium Difficile Infection Recurrence — all drugs for Clostridium Difficile Infection Recurrence →
Clostridium Difficile Infection — all drugs for Clostridium Difficile Infection →

Sponsor

Krunal Patel

Who can join

16 and older, any sex, with Clostridium Difficile Infection Recurrence or Clostridium Difficile Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection of the colon. During the procedure a stool sample is taken from a healthy donor (usually family member or close friend) and transplanted directly into the colon of the patient with C. diff infection. The goal of this experimental procedure (called fecal microbiota transplantation) is to replenish the good bacteria in the colon that can help prevent C. diff infection from coming back after treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The development of live biotherapeutics against <i>Clostridioides difficile</i> infection towards reconstituting gut microbiota.
Zhang Y, Saint Fleur A, Feng H. · · 2022 · cited 23× · PMID 35319337 · DOI 10.1080/19490976.2022.2052698
Frontiers in antibiotic alternatives for <i>Clostridioides difficile</i> infection.
Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, et al · · 2021 · cited 12× · PMID 34876784 · DOI 10.3748/wjg.v27.i42.7210

Verify or expand the search:

Other trials of Fecal Microbiota Transplantation

Trials testing the same drug.

NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07454408 — Evaluation of the Outcome of Fecal Microbiota Transplantation · Phase 1, PHASE2 · not yet recruiting
NCT07463248 — PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line · Phase 2 · not yet recruiting
NCT07042438 — Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo · Phase 2 · recruiting
NCT06744751 — A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN · NA · not yet recruiting

Other recruiting trials for Clostridium Difficile Infection Recurrence

Currently open trials in the same condition.

NCT07261826 — Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03562741 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Krunal Patel
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03562741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing